|
|
|
|
Search: 
Latin American Herald Tribune
Venezuela Overview
Venezuelan Embassies & Consulates Around The World
Sites/Blogs about Venezuela
Venezuelan Newspapers
Facts about Venezuela
Venezuela Tourism
Embassies in Caracas

Colombia Overview
Colombian Embassies & Consulates Around the World
Government Links
Embassies in Bogota
Media
Sites/Blogs about Colombia
Educational Institutions

Stocks

Commodities
Crude Oil
US Gasoline Prices
Natural Gas
Gold
Silver
Copper

Euro
UK Pound
Australia Dollar
Canada Dollar
Brazil Real
Mexico Peso
India Rupee

Antigua & Barbuda
Aruba
Barbados
Cayman Islands
Cuba
Curacao
Dominica

Grenada
Haiti
Jamaica
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines

Belize
Costa Rica
El Salvador
Honduras
Nicaragua
Panama

Bahamas
Bermuda
Mexico

Argentina
Brazil
Chile
Guyana
Paraguay
Peru
Uruguay

What's New at LAHT?
Follow Us On Facebook
Follow Us On Twitter
Most Viewed on the Web
Popular on Twitter
Receive Our Daily Headlines


  HOME | Argentina

Argentina’s Insud Announces Biotech Investments Totaling More Than $80 Million

BUENOS AIRES – The Insud Group, an Argentine business conglomerate operating in 40 countries, announced investments of more than $80 million for clinical studies in Argentina on latest-generation medications.

The announcement was made on Tuesday at the Bio International Convention, a biotech fair being held in San Diego, California, and the studies will be conducted by the mAbxience company, which belongs to the group, Insud reported Wednesday.

The clinical trials will be carried out on two monoclonal antibodies: adalimumab – which is used to treat and prevent rheumatoid arthritis and various kinds of psoriasis – and palivizumab, designed for the preventive treatment of respiratory syncytial virus (RSV), one of the main causes of infant deaths, according to the World Health Organization.

The development of palivizumab is part of an agreement signed by the WHO, the Dutch Utrecht Excellence Center for Affordable Biotherapeutics and mAbxience.

When these monoclonal antibodies are authorized for use among the general public, after the clinical trials, they will be manufactured in the biotech medications plant that mAbxience has in the city of Munro in Buenos Aires province.

The event to announce the project was attended by Argentine Health Ministry chief of staff Enrique Chiantore and Argentine Medications Registration and Evaluation Directorate representative Valeria Palaviccini, along with officials with the Science, Technology and Productive Innovation Ministry and top figures within Grupo Insud.

The Bio International Convention is the world’s largest and most important biotech gathering, drawing more than 5,000 companies, academic institutions and organizations specializing in biotechnology as applied to health, agriculture and the environment in more than 60 countries.

 

Enter your email address to subscribe to free headlines (and great cartoons so every email has a happy ending!) from the Latin American Herald Tribune:

 

Copyright Latin American Herald Tribune - 2005-2018 © All rights reserved